Vasoresponsiveness of Sarcoidosis-Associated Pulmonary Hypertension

摘要: Objective: To assess short-term and long-term responses to treatment with pulmonary vasodilators in patients sarcoidosis-related hypertension. Methods: A prospective, observational study was performed on eight moderate-tosevere Patients underwent a vasodilator trial, using inhaled nitric oxide (iNO), IV epoprostenol, and/or oral calcium-channel blockers. favorable response considered > 20% decrease vascular resistance (PVR). Five received iNO (with one patient receiving epoprostenol addition) follow-up hemodynamic 6-min walk testing. Two Results: Baseline ( SE) mean artery pressure (mPAP) 55 4 mm Hg PVR 896 200 dynescm 5 . seen seven of iNO, four six two five With decreased 31 5% (p 0.006) mPAP 18 4% 0.003); 25 6% 0.016) 6 2% not significant). Decreased systemic the only significant Follow-up test results improved all iNO. three showed preserved vasoresponsiveness. These subsequently died, as did The remaining continue receive Conclusion: In short term, hypertension sarcoidosis is responsive vasodilators; these may benefit from therapy. (CHEST 2001; 120:866 – 872)